TNF/TNFR1 signaling mediates doxorubicin-induced diaphragm weakness.
about
Docetaxel does not impair skeletal muscle force production in a murine model of cancer chemotherapyCyclophosphamide leads to persistent deficits in physical performance and in vivo mitochondria function in a mouse model of chemotherapy late effects.Neutral sphingomyelinase-3 mediates TNF-stimulated oxidant activity in skeletal muscleEffects of short-term endurance exercise training on acute doxorubicin-induced FoxO transcription in cardiac and skeletal muscle.Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress.TNF signals via neuronal-type nitric oxide synthase and reactive oxygen species to depress specific force of skeletal muscle.Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes.The anticancer agent doxorubicin disrupts mitochondrial energy metabolism and redox balance in skeletal muscle.Doxorubicin inhibits muscle inflammation after eccentric exercise.Targeted overexpression of mitochondrial catalase protects against cancer chemotherapy-induced skeletal muscle dysfunction.
P2860
Q33800180-90893A7D-0A8C-480F-B6E9-172EF92F6FF3Q33897890-AFD189D8-5FBC-41FB-A4D0-6B61BA3CA7E1Q34085972-06435570-4243-4AFD-B245-3566112457F9Q35141318-E887A584-91B4-4925-BD5C-A013FB5C2746Q35222202-3FA74BF6-355E-4F01-A101-01B50390696EQ36924162-DC3CD391-376F-4589-9640-DD315ECFAC4CQ37282125-4832D882-70D6-4AB9-B183-A092E719A57BQ37384579-6EF01124-C950-4561-9A23-006BB19509FFQ37734801-0D670413-D3CA-4F00-A00D-EBE92C2BD5E9Q40982094-3BBF1034-FE16-44C7-A473-3B3EE808EF35
P2860
TNF/TNFR1 signaling mediates doxorubicin-induced diaphragm weakness.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
TNF/TNFR1 signaling mediates doxorubicin-induced diaphragm weakness.
@ast
TNF/TNFR1 signaling mediates doxorubicin-induced diaphragm weakness.
@en
TNF/TNFR1 signaling mediates doxorubicin-induced diaphragm weakness.
@nl
type
label
TNF/TNFR1 signaling mediates doxorubicin-induced diaphragm weakness.
@ast
TNF/TNFR1 signaling mediates doxorubicin-induced diaphragm weakness.
@en
TNF/TNFR1 signaling mediates doxorubicin-induced diaphragm weakness.
@nl
prefLabel
TNF/TNFR1 signaling mediates doxorubicin-induced diaphragm weakness.
@ast
TNF/TNFR1 signaling mediates doxorubicin-induced diaphragm weakness.
@en
TNF/TNFR1 signaling mediates doxorubicin-induced diaphragm weakness.
@nl
P2093
P2860
P1476
TNF/TNFR1 signaling mediates doxorubicin-induced diaphragm weakness.
@en
P2093
Jennifer S Moylan
Laura A A Gilliam
Leonardo F Ferreira
Michael B Reid
P2860
P304
P356
10.1152/AJPLUNG.00264.2010
P577
2010-11-19T00:00:00Z